CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction

CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction

Summary: Background: Use of adjuvant chemotherapy in patients with early-stage lung cancer is controversial because no definite biomarker exists to identify patients who would receive added benefit from it. We aimed to develop and validate a quantitative radiomic risk score (QuRiS) and associated n...

Full description

Bibliographic Details
Main Authors: Pranjal Vaidya, BS, Kaustav Bera, MD, Amit Gupta, MD, Xiangxue Wang, PhD, Germán Corredor, PhD, Pingfu Fu, PhD, Niha Beig, MS, Prateek Prasanna, PhD, Pradnya D Patil, MD, Priya D Velu, MD, Prabhakar Rajiah, MD, Robert Gilkeson, MD, Michael D Feldman, MD, Humberto Choi, MD, Vamsidhar Velcheti, MD, Anant Madabhushi, ProfPhD
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:The Lancet: Digital Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2589750020300029

Internet

http://www.sciencedirect.com/science/article/pii/S2589750020300029

Similar Items